January 31, 2022
2 mins read

NHS expands Covid vaccines to at-risk 5 to 11-year-old kids

The NHS had earlier opened up vaccines for the over 12 age group and said it has delivered over 3.5 million vaccinations to people aged 12-17, including over 2.4 million first doses…reports Asian Lite News

The UK’s National Health Service (NHS) on Sunday expanded its COVID-19 vaccination programme to cover vulnerable children aged five to 11 years.

Eligible children include those with diabetes, immunosuppression, learning disabilities, and other serious conditions that place them at high risk from COVID-19.

NHS England said nearly 500,000 eligible children in England are set to receive their first dose of a COVID vaccine in line with advice set out by the Joint Committee on Vaccination and Immunisation (JCVI).

We know vaccines give significant protection against severe illness from COVID including the Omicron variant, so it is important that our youngest and most at-risk get protected, said Dr Nikki Kanani, an Indian-origin GP and deputy lead for NHS vaccination programme.

The NHS is now vaccinating the most at risk 511-year-olds ensuring they get their vital dose of protection. Thousands of young people are still getting protected every day with millions vaccinated so far and we are asking parents not to delay coming forward as soon as the NHS contacts you, please come forward so the NHS can protect their youngest against the virus, she said.

The NHS had earlier opened up vaccines for the over 12 age group and said it has delivered over 3.5 million vaccinations to people aged 12-17, including over 2.4 million first doses.

UK Vaccines Minister Maggie Throup said: I would like parents and guardians to be reassured that no new vaccine for children would have been approved unless the expected standards of safety, quality and effectiveness had been met.

I encourage as many as possible to make sure they get their child the jab when contacted – the paediatric vaccine will offer the best possible protection for your child.

In line with procedures, patient information is sent out to parents and guardians with information on the COVID-19 vaccination. Parents and guardians are asked to attend with their children and are asked to read the patient information in advance of arriving for their appointment.

Photo Credits: Richard Townshend/ UK Parliament

Eligible children in the youngest cohort will get a second dose eight weeks after their first dose and can’t receive any vaccination until four weeks after a positive test for coronavirus.

Last month, the JCVI also issued updated guidance recommending all 16 and 17-year-olds get a Pfizer/BioNTech booster from three months (91 days) after their second dose. Following the expansion of a third booster vaccine for all 16 and 17-year-olds, over half of the eligible young people in this age group have already received their top-up protection.

ALSO READ-‘We are the NHS’

Previous Story

Baloch situation turning from bad to worse

Next Story

US shutters Afghan embassy

Latest from -Top News

Mass Expulsions Close Afghan Shops in Pakistan

As Pakistan intensifies its mass deportation drive against Afghan refugees, the once-bustling Afghan-owned businesses in Rawalpindi are falling silent. With the March 31 deadline for repatriation passed, a growing number of Afghan-run

South Korea Sets June 3 Presidential Election

South Korea will hold a presidential election on June 3, the government confirmed on Tuesday, setting the stage for a new leadership following the impeachment and removal of former President Yoon Suk

RPP Rallies for Return of Nepal’s Monarchy

Police on alert as royalist rallies return to the capital Kathmandu witnessed heightened tensions on Tuesday as the pro-monarchy Rastriya Prajatantra Party (RPP) staged a high-profile demonstration demanding the reinstatement of Nepal’s
Go toTop

Don't Miss

Delhi gears up to handle 1 lakh daily cases amid Omicron scare

The government will also increase the daily Covid testing capacity

WHO approves Covaxin, Health Minister hails scientists

Developed by Bharat Biotech in partnership with the ICMR and